LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Back to previous search Search history
Advanced search

Your last searches

  1. AU="Kwong, A S K"
  2. AU="Hadian, Marziye"
  3. AU="Chen, Yaying"
  4. AU="Ortega, Francisco B"
  5. AU=Cobb Samuel N
  6. AU="Abdelmohssin El Mokaddem"
  7. AU="Iwao Ojima"
  8. AU="Abazi, Sokol"
  9. AU="Cook, Rebecca"
  10. AU=Martin Flavius
  11. AU="Cipriani, Raffaela"
  12. AU="Levin, Michael E."
  13. AU="Yang, Dayu"

Search results

Result 1 - 2 of total 2

Search options

  1. Article: Screening interval for diabetic retinopathy: a personalised approach (abridged secondary publication).

    Lian, J / Lam, C L K / Thach, T Q / McGhee, S / Fung, C S C / Kwong, A S K / Chau, C K V / Chan, J C H

    Hong Kong medical journal = Xianggang yi xue za zhi

    2023  Volume 29 Suppl 3, Issue 3, Page(s) 33–35

    MeSH term(s) Humans ; Diabetic Retinopathy/diagnosis ; Diabetes Mellitus, Type 2/complications ; Mass Screening
    Language English
    Publishing date 2023-06-26
    Publishing country China
    Document type Journal Article
    ZDB-ID 1239255-8
    ISSN 1024-2708
    ISSN 1024-2708
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4347: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Cross-clade immunogenicity and safety of an AS03A-adjuvanted prepandemic H5N1 influenza vaccine in Hong Kong.

    Chu, D W S / Kwong, A S K / Tsui, W W S / Wang, J H L / Ngai, C K H / Wan, P K T / Ong, G / Tang, H W / Roman, F / Dram, M / Bock, H L

    Hong Kong medical journal = Xianggang yi xue za zhi

    2011  Volume 17, Issue 1, Page(s) 39–46

    Abstract: Objective: To present Hong Kong'Äìspecific data from a large Asian population (also involving Thailand, Singapore, and Taiwan) on safety and manufacturing consistency across four AS03(A)-adjuvanted H5N1 vaccine formulations in terms of immune response ... ...

    Abstract Objective: To present Hong Kong'Äìspecific data from a large Asian population (also involving Thailand, Singapore, and Taiwan) on safety and manufacturing consistency across four AS03(A)-adjuvanted H5N1 vaccine formulations in terms of immune response against the A/Vietnam/1194/2004 strain. Immunogenicity against the heterologous A/Indonesia/05/2005 strain was also assessed. NCT Number: 00449670.
    Design: Prospective, observer-blind study.
    Setting: Out-patient clinic of a tertiary hospital in Hong Kong.
    Participants: A total of 360 subjects aged 18 to 60 years were randomised into six groups to receive two doses (21 days apart) of the study vaccine.
    Interventions: One of the four adjuvanted formulations (3.75 microgram H5N1 haemagglutinin [HA]+AS03(A)) of the vaccine (H5N1-AS03(A)) or one of the two non-adjuvanted (3.75 microgram H5N1 [HA]) formulations of the vaccine (H5N1-DIL).
    Main outcome measures: Blood samples collected before vaccination and 21 days after each vaccine dose were analysed using haemagglutination-inhibition and neutralisation assays. Solicited, unsolicited, and serious adverse events were recorded.
    Results: Manufacturing consistency across all four vaccine formulations was demonstrated. After two doses, the AS03(A)-adjuvanted prepandemic influenza vaccine demonstrated high seroprotection rates against the A/Vietnam/1194/2004 strain (95.8%) and good immunogenicity against the heterologous A/Indonesia/05/2005 strain (45.7%), as compared to the non-adjuvanted vaccine (4.6% and 1.5%, respectively). The seroconversion rates induced by the adjuvanted formulations in terms of viral neutralising antibodies against the two strains were much higher than those induced by the non-adjuvanted formulations. There were no safety concerns for any of the adjuvanted vaccine formulations.
    Conclusions: The AS03(A)-adjuvanted H5N1 prepandemic influenza vaccine demonstrated good immunogenicity and an acceptable safety profile in Hong Kong.
    MeSH term(s) Adult ; Antibodies, Viral/blood ; Female ; Hong Kong ; Humans ; Influenza A Virus, H5N1 Subtype/immunology ; Influenza Vaccines/adverse effects ; Influenza Vaccines/immunology ; Male ; Pandemics ; Prospective Studies
    Chemical Substances Antibodies, Viral ; Influenza Vaccines
    Language English
    Publishing date 2011-02
    Publishing country China
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 1239255-8
    ISSN 1024-2708
    ISSN 1024-2708
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4347: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top